Pain duration (mean pain duration, assessed at 4 weeks) · Children with recurrent abdominal pain
It is very uncertain whether antispasmodics changes pain duration (mean pain duration, assessed at 4 weeks) compared with placebo (very low certainty).
1 finding from 1 review
Pain improvement (clinician judged, assessed at 2 weeks) · Children with recurrent abdominal pain
It is very uncertain whether antispasmodics changes pain improvement (clinician judged, assessed at 2 weeks) compared with placebo (very low certainty).
1 finding from 1 review
Pain episodes · Children with recurrent abdominal pain
It is very uncertain whether antispasmodics changes pain frequency (episodes of pain in 4 weeks, assessed after 4 weeks) compared with placebo (very low certainty).
1 finding from 1 review
Pain improvement (self reported response to treatment, assessed at 4 weeks) · Children with recurrent abdominal pain
Antispasmodics showed no clear difference in pain improvement (self reported response to treatment, assessed at 4… compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Uncorrected visual acuity (UCVA) of 20/20 or better · participants aged 18‐60 years with myopia ranging in severity up to 12 diopters (D)
It is very uncertain whether the intervention changes uncorrected visual acuity (UCVA) of 20/20 or better (very low certainty).
1 finding from 1 review
RR 0.96 [0.82, 1.13]
Studies not reported
Very low
Intervention not reported
Uncorrected visual acuity (UCVA) of 20/40 or better · participants aged 18‐60 years with myopia ranging in severity up to 12 diopters (D)
It is very uncertain whether the intervention changes uncorrected visual acuity (UCVA) of 20/40 or better (very low certainty).
1 finding from 1 review
RR 0.9 [0.67, 1.21]
Studies not reported
Very low
Intervention not reported
Proportion of participants who lost two or more lines of best‐corrected visual acuity (BCVA) · participants aged 18‐60 years with myopia ranging in severity up to 12 diopters (D)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Eyes within ± 0.5 D of target refraction · participants aged 18‐60 years with myopia ranging in severity up to 12 diopters (D)
It is very uncertain whether the intervention changes eyes within ± 0.5 D of target refraction (very low certainty).
1 finding from 1 review
RR 0.69 [0.48, 0.99]
Studies not reported
Very low
Intervention not reported
Postoperative corneal haze · participants aged 18‐60 years with myopia ranging in severity up to 12 diopters (D)
It is very uncertain whether the intervention changes postoperative corneal haze (very low certainty).
1 finding from 1 review
RR 2.11 [0.57, 7.82]
Studies not reported
Very low
Intervention not reported
Postoperative pain score: 1 year · participants aged 18‐60 years with myopia ranging in severity up to 12 diopters (D)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events (flap‐complications) · participants aged 18‐60 years with myopia ranging in severity up to 12 diopters (D)
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Inattention Measured using SNAP‐IV inattention subscale (range 0 to 27) · Children aged 6 to 18 years with ASD
2 findings from 1 review
Impulsivity · Children aged 6 to 18 years with ASD
2 findings from 1 review
Hyperactivity · Children aged 6 to 18 years with ASD
2 findings from 1 review
Impaired social interaction · Children aged 6 to 18 years with ASD
2 findings from 1 review
Impaired communication · Children aged 6 to 18 years with ASD
2 findings from 1 review
Stereotypical behaviours · Children aged 6 to 18 years with ASD
2 findings from 1 review
Overall ASD · Children aged 6 to 18 years with ASD
2 findings from 1 review
Total number of adverse events · Children aged 6 to 18 years with ASD
2 findings from 1 review
Recurrent venous thromboembolism · people > 18 years of age with a diagnosed deep vein thrombosis
Fondaparinux plus vitamin K antagonist showed no clear difference in recurrent venous thromboembolism compared with standard therapy (moderate certainty).
1 finding from 1 review